Organization
Celgene Corporation
10 abstracts
Abstract
APREMILAST MONOTHERAPY AS THE FIRST SYSTEMIC TREATMENT IN DMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR TREATMENT RESULTS Org: Celgene Corporation, West Tennessee Research Institute, Rheumatology and Immunotherapy Center, Franklin, United States of America, Altoona Center for Clinical Research, Duncansville, United States of America, Combined Rheumatology Practice, Kogarah,
Abstract
ACHIEVEMENT OF RAPID3 NEAR REMISSION OR LOW SEVERITY IS ASSOCIATED WITH RESIDUAL LEVELS OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILASTOrg: Celgene Corporation, Crozer-Keystone Health System, Nuffield Department of Orthopaedics, Rhuematology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, Arthritis and Musculoskeletal Center, University of California, San Diego, School of Medicine,
Abstract
5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studiesOrg: Celgene Corporation, Krembil Research Institute, University of California, San Diego, School of Medicine, Swedish Medical Center, University of Washington School of Medicine,
Abstract
APREMILAST TREATMENT AND LONG-TERM (UP TO 156 WEEKS) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF A LARGE DATABASE OF THE PHASE III CLINICAL DEVELOPMENT PROGRAM Org: Celgene Corporation,
Abstract
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING-DOSE, SAFETY STUDY OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Org: University of Pennsylvania School of Medicine, Northwell Health, New Hyde Park, NY, Celgene Corporation,
Abstract
A PHASE IV, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST ON HAND AND WHOLE-BODY MRI OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS (MOSAIC): RATIONALE, DESIGN AND METHODSOrg: Celgene Corporation, Image Analysis Group,
Abstract
AIOLOS OVEREXPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS B-CELL SUBTYPES AND BAFF INDUCED MEMORY B-CELL DIFFERENTIATION ARE REDUCED BY CC-220 MODULATION OF CEREBLON ACTIVITY Org: Celgene Corporation,
Abstract
ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILASTOrg: Celgene Corporation, Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: Celgene Corporation, University Hospital Southampton NHS Foundation Trust, Rheumatology and Immunotherapy Center, Franklin, United States of America, University of Sheffield, Altoona Center for Clinical Research, Duncansville, United States of America,
Abstract
Apremilast for behÇet’s syndrome: a phase iii randomised, placebo-controlled, double-blind study (RELIEF)Org: Celgene Corporation,